Something shifted in Washington this week that millions of Americans who take antidepressants will want to pay attention to. It didn’t come from a hospital, a medical journal, or a professional association. It came from the federal government, and it’s already dividing the psychiatric community in ways rarely seen in recent memory.
The debate at the center of it is one that many people quietly carry but rarely raise with their doctors: are we, as a country, prescribing too many psychiatric medications? And if some people are on drugs they no longer need, or drugs that were never right for them in the first place, what should happen next? The answers aren’t simple. But the questions are long overdue.
What’s happening right now sits at the intersection of federal policy, individual health, and a genuine gap in how the mental health system handles both starting and stopping medication. Whether you take antidepressants yourself, know someone who does, or simply watch healthcare policy with a critical eye, this is a story worth understanding carefully.
What the Federal Government Just Announced
HHS Secretary Robert F. Kennedy Jr. announced a plan to reduce “overprescribing” of psychiatric medications and support alternative treatment options and discontinuation of medications when needed. Speaking at a Make America Healthy Again Institute summit, Kennedy said the effort will emphasize the appropriate deprescribing of psychiatric drugs while shifting care toward prevention and more holistic treatment approaches.
The plan has several concrete components. A “Dear Colleague” letter from the Substance Abuse and Mental Health Services Administration urges clinicians to prioritize informed consent, shared decision-making, and non-pharmaceutical treatments such as psychotherapy, exercise, nutrition, and family support. New guidance from the Centers for Medicare and Medicaid Services also allows reimbursement for time spent monitoring withdrawal and assisting patients with discontinuation. HHS will also convene a technical expert panel to develop clinical guidelines for deprescribing, and this summer SAMHSA will release training modules focusing on the risks of psychiatric medications and how to taper them.
The initiative focuses on the most widely prescribed class of psychiatric medications – SSRIs (selective serotonin reuptake inhibitors), which include Zoloft, Lexapro, Paxil, and Prozac. As of 2026, roughly 16.6% of U.S. adults, about 1 in 6, report currently taking an SSRI. Introduced nearly 40 years ago, the drugs surged in popularity partly because they had fewer side effects than earlier antidepressants and could be prescribed by general practitioners, not just psychiatrists.
What “Overprescribing” and “Deprescribing” Actually Mean
These two terms are getting a lot of airtime, but they’re being used loosely in ways that can confuse more than clarify.
Overprescribing refers to the idea of clinicians prescribing medications to patients who may not need them, depending on the causes or severity of their symptoms or whether they have first tried other non-medication interventions. The concept also describes someone taking medications longer than necessary, or taking drugs that aren’t effective for them.
Deprescribing sounds alarming at first glance, but it’s a clinical concept that has existed in medicine for years. According to the official SAMHSA guidance issued alongside this announcement, deprescribing is not synonymous with abrupt discontinuation or blanket medication reduction. Rather, it is a deliberate, individualized clinical process that may be appropriate when treatment goals have been met, when adverse effects create unnecessary burden, when a medication hasn’t provided meaningful benefit, or when a patient’s informed preferences support a carefully monitored taper.
Dr. Joseph F. Goldberg, a clinical professor of psychiatry at the Icahn School of Medicine at Mount Sinai in New York City, said to CNN, “If any treatment is not proving itself to be beneficial, or if problems with tolerability substantially outweigh efficacy, it makes sense to discontinue that treatment and replace it with a more effective viable alternative.”
That framing is hard to argue with. The real debate isn’t about that principle. It’s about whether the federal government should be the one driving it, and whether the emphasis is balanced.
Why Psychiatrists Are Pushing Back
The response from the psychiatric community has been measured but pointed. Dr. Theresa Miskimen Rivera, president of the American Psychiatric Association, said the group supports the administration’s plans for further investment, research, and clinical training. However, she added: “We do have an issue with the framing of mental health as a primary problem of overmedicalization.” In her view, that characterization “really oversimplifies a very complex, larger issue.”
Dr. Jonathan Alpert, of Montefiore Medical Center in New York City, offered a more direct reframe: “As with all areas of medicine, we should be concerned about both overprescribing and underprescribing. In some instances, antibiotics or diabetes medications are overprescribed and cause unnecessary side effects, cost and other harms. In many other instances, they can be lifesaving. So too with psychiatric medications such as antidepressants or antipsychotics.”
Dr. Goldberg added a statistic that puts the underprescribing concern in context: “Depression remains the leading cause of disability in the world.” In recent years, only about 40% of adults and adolescents with depression in the United States received counseling or therapy, and just 11.4% of adults took prescription medication for depression.
The American Psychiatric Association also pointed to the structural failures driving the mental health crisis: access problems, workforce shortages, limited psychiatric beds, barriers to psychotherapy and social supports, and a lack of integrated care. In other words, the problem isn’t only that some people are on too many pills. For a large number of Americans, the problem is they can’t access care at all.
The American Foundation for Suicide Prevention also weighed in, cautioning that non-collaborative or abrupt deprescribing may cause symptom relapse and elevate suicide risk, underscoring the need for individualized assessment, patient-centered communication, and close follow-up.
The Rising Prescription Trend – Especially in Young People
One area where there’s genuine clinical concern, and where the federal focus on children has some data behind it, involves the sharp rise in antidepressant prescribing among younger Americans. This isn’t a political talking point – it’s documented in peer-reviewed research.
According to a 2024 study published in Pediatrics, the monthly antidepressant-dispensing rate for U.S. adolescents and young adults aged 12 to 25 increased by 66.3% between 2016 and 2022. Monthly rates were also 63.5% higher from March 2020 to December 2022 compared with rates prior to the pandemic.
Among female adolescents aged 12 to 17, antidepressant-dispensing rates were 129.6% higher after March 2020 compared with before – more than double, in just a few years. Researchers noted that rising rates of depression and anxiety among young people, particularly girls, were driving much of this change, and that pandemic-related stress and previous mental health conditions may have contributed, as may have increased access to mental healthcare resources.
That’s an important nuance. A rise in prescriptions doesn’t automatically mean overprescribing. It may simply reflect a population in greater distress getting more treatment. The concern arises when prescriptions are dispensed without adequate assessment, when non-drug options aren’t offered or explained, or when patients are never re-evaluated for whether medication is still needed.
The question of what happens when people stop is equally important. SSRIs are not habit-forming in the traditional sense. But according to the Mayo Clinic, stopping antidepressant treatment suddenly or missing several doses can cause withdrawal-like symptoms – a reality that many patients encounter without adequate preparation or support from their prescribers.
The Safety Question: What the Science Actually Says
Although some slight risks of harm have been found in specific situations, these medications have been deemed by the U.S. Food and Drug Administration as generally safe and effective for mental health disorders, including depression, anxiety, eating disorders, substance use disorder, and obsessive-compulsive disorder.
Kennedy has made some sweeping claims about these drugs that go beyond what the evidence supports. He has claimed that the drugs are overused and that they may be linked with violence and mass shootings, with serious risks to developing fetuses when women take them during pregnancy, with withdrawal worse than that from heroin, and with harms to children. Some of these concerns have partial support in limited research. Others – particularly the comparisons to heroin withdrawal and the link to mass violence – are not supported by mainstream scientific consensus.
From a clinical standpoint, what is well-established is that abrupt cessation of antidepressants can cause discontinuation syndrome, a transient cluster of symptoms such as dizziness, insomnia, and flu-like feelings, that typically resolves with dose tapering. That’s a real concern worth taking seriously. It’s also a reason why the new CMS reimbursement pathway for supervised tapering has been broadly welcomed by clinicians, even those critical of the initiative’s framing.
The collective intent of these policy moves appears to be a shift toward shared decision-making, informed consent, and greater integration of non-drug interventions such as psychotherapy, exercise, and nutrition – none of which are controversial in clinical psychiatry. The controversy is in the degree to which overprescribing is named as a primary driver of the mental health crisis, when access failures may be the bigger culprit.
Read More: How Your Medications Could Be Changing Who You Are
What This Means for You
If you’re currently taking an antidepressant or any psychiatric medication, nothing about this announcement means you should stop, reduce your dose, or change your treatment. That decision belongs to you and your doctor, made based on your individual circumstances and your response to treatment. What has changed is the policy environment around that conversation.
The new CMS guidance means your doctor can now be reimbursed under Medicare for the time spent helping you taper off a medication safely, if that’s clinically appropriate. That’s meaningful. Many patients report that clinicians previously told them going off SSRIs was straightforward, but then experienced significant withdrawal symptoms, including “brain zaps,” restlessness, and flu-like symptoms, with little support in the process. Having that time covered and reimbursed should make those conversations more accessible.
The real tension at the center of this policy push is this: some Americans genuinely do want off antidepressants, yet the clinical evidence says the path off them must be supervised, gradual, and individualized. If this initiative pushes the healthcare system toward better-informed prescribing, genuine shared decision-making, and real support for patients who want to taper safely, that’s a good outcome. If it discourages people who genuinely need psychiatric medication from seeking or continuing treatment, it could do real harm.
The best thing any individual can do right now is be informed. Ask your prescriber when your medication was last reassessed. Ask whether non-drug options were ever fully explored alongside medication. And if you’re considering any change to your psychiatric treatment, do it with clinical supervision, not in response to a political headline.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Psychedelic Therapy Shows Promise for Long-Term Depression Relief